Submit Search
Upload
Who hiv 2012.28_eng
•
1 like
•
317 views
clac.cab
Follow
Health & Medicine
Report
Share
Report
Share
1 of 19
Download now
Download to read offline
Recommended
A presentation of a new adverse drug event evidence base (Laertes - http://goo.gl/nZSqVw) within a standard framework for clinical research (OHDSI - www.ohdsi.org) made at the American Medical Informatics Association Joint Summits on Translational Research on 3/26/2015
Piloting a Comprehensive Knowledge Base for Pharmacovigilance Using Standardi...
Piloting a Comprehensive Knowledge Base for Pharmacovigilance Using Standardi...
Richard Boyce, PhD
An overview of the research aims for the National Library of Medicine funded research project titled "Addressing gaps in clinically useful evidence on drug-drug interactions" (1R01LM011838-01)
Addressing gaps-in-clinically-useful-evidence-on-dd is-nlm-training-2014
Addressing gaps-in-clinically-useful-evidence-on-dd is-nlm-training-2014
Richard Boyce, PhD
Prof. Boyce discusses the "Linked SPLs" system its relationship to SPLs stored in DailyMed and the OpenFDA initiative. The talk will focus on the potential uses, strengths, and limitations Linked SPLs which represents drug product labeling as Semantic Web Linked Data. Video of this talk can be found at the link below starting at starts at 3:11:26: http://videocast.nih.gov/summary.asp?Live=14776&bhcp=1
Linked data-and-sp ls-fda-spl-jamboree-092014
Linked data-and-sp ls-fda-spl-jamboree-092014
Richard Boyce, PhD
PowerPoint Presentation from May 2011 Personal Validation and Entity Resolution Conference. Presenter: Andrew Bate
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
NORC at the University of Chicago
A look at the IVD kit market for Zika, Ebola and the market considerations of emerging infectious disease tests.
Molecular Test Approaches to Zika, Ebola, Other
Molecular Test Approaches to Zika, Ebola, Other
Bruce Carlson
With its focus on investigating the nature and basis for the sustained existence of living systems, modern biology has always been a fertile, if not challenging, domain for formal knowledge representation and automated reasoning. Over the past 15 years, hundreds of projects have developed or leveraged ontologies for entity recognition and relation extraction, semantic annotation, data integration, query answering, consistency checking, association mining and other forms of knowledge discovery. In this talk, I will discuss our efforts to build a rich foundational network of ontology-annotated linked data, discover significant biological associations across these data using a set of partially overlapping ontologies, and identify new avenues for drug discovery by applying measures of semantic similarity over phenotypic descriptions. As the portfolio of Semantic Web technologies continue to mature in terms of functionality, scalability and an understanding of how to maximize their value, increasing numbers of biomedical researchers will be strategically poised to pursue increasingly sophisticated KR projects aimed at improving our overall understanding of the capability and behavior of biological systems.
Generating Biomedical Hypotheses Using Semantic Web Technologies
Generating Biomedical Hypotheses Using Semantic Web Technologies
Michel Dumontier
Mobilizing informational resources for rare diseases
Mobilizing informational resources webinar
Mobilizing informational resources webinar
Ann-Marie Roche
Determining the cellular mechanisms of diseases is a crucial requirement for understanding the causes and progression of diseases, predicting outcomes, and developing new treatments. Often relevant information, e.g. what cells are involved in a disease or what effects does a drug have on cells, is scattered across many papers and journals, which makes it difficult for researchers to be sure they have a complete picture. Using Elsevier’s automated text mining technology, we have created a new cell-centered database consisting of 850 000 facts captured from more than 24 million PubMed abstracts and 3.5 million full text articles for use in Pathway Studio. This database focused primarily on cellular aspects of immunology and immuno-oncology can be used to summarize and visualize published research, and to analyze experimental data.
Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016
Ann-Marie Roche
Recommended
A presentation of a new adverse drug event evidence base (Laertes - http://goo.gl/nZSqVw) within a standard framework for clinical research (OHDSI - www.ohdsi.org) made at the American Medical Informatics Association Joint Summits on Translational Research on 3/26/2015
Piloting a Comprehensive Knowledge Base for Pharmacovigilance Using Standardi...
Piloting a Comprehensive Knowledge Base for Pharmacovigilance Using Standardi...
Richard Boyce, PhD
An overview of the research aims for the National Library of Medicine funded research project titled "Addressing gaps in clinically useful evidence on drug-drug interactions" (1R01LM011838-01)
Addressing gaps-in-clinically-useful-evidence-on-dd is-nlm-training-2014
Addressing gaps-in-clinically-useful-evidence-on-dd is-nlm-training-2014
Richard Boyce, PhD
Prof. Boyce discusses the "Linked SPLs" system its relationship to SPLs stored in DailyMed and the OpenFDA initiative. The talk will focus on the potential uses, strengths, and limitations Linked SPLs which represents drug product labeling as Semantic Web Linked Data. Video of this talk can be found at the link below starting at starts at 3:11:26: http://videocast.nih.gov/summary.asp?Live=14776&bhcp=1
Linked data-and-sp ls-fda-spl-jamboree-092014
Linked data-and-sp ls-fda-spl-jamboree-092014
Richard Boyce, PhD
PowerPoint Presentation from May 2011 Personal Validation and Entity Resolution Conference. Presenter: Andrew Bate
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
NORC at the University of Chicago
A look at the IVD kit market for Zika, Ebola and the market considerations of emerging infectious disease tests.
Molecular Test Approaches to Zika, Ebola, Other
Molecular Test Approaches to Zika, Ebola, Other
Bruce Carlson
With its focus on investigating the nature and basis for the sustained existence of living systems, modern biology has always been a fertile, if not challenging, domain for formal knowledge representation and automated reasoning. Over the past 15 years, hundreds of projects have developed or leveraged ontologies for entity recognition and relation extraction, semantic annotation, data integration, query answering, consistency checking, association mining and other forms of knowledge discovery. In this talk, I will discuss our efforts to build a rich foundational network of ontology-annotated linked data, discover significant biological associations across these data using a set of partially overlapping ontologies, and identify new avenues for drug discovery by applying measures of semantic similarity over phenotypic descriptions. As the portfolio of Semantic Web technologies continue to mature in terms of functionality, scalability and an understanding of how to maximize their value, increasing numbers of biomedical researchers will be strategically poised to pursue increasingly sophisticated KR projects aimed at improving our overall understanding of the capability and behavior of biological systems.
Generating Biomedical Hypotheses Using Semantic Web Technologies
Generating Biomedical Hypotheses Using Semantic Web Technologies
Michel Dumontier
Mobilizing informational resources for rare diseases
Mobilizing informational resources webinar
Mobilizing informational resources webinar
Ann-Marie Roche
Determining the cellular mechanisms of diseases is a crucial requirement for understanding the causes and progression of diseases, predicting outcomes, and developing new treatments. Often relevant information, e.g. what cells are involved in a disease or what effects does a drug have on cells, is scattered across many papers and journals, which makes it difficult for researchers to be sure they have a complete picture. Using Elsevier’s automated text mining technology, we have created a new cell-centered database consisting of 850 000 facts captured from more than 24 million PubMed abstracts and 3.5 million full text articles for use in Pathway Studio. This database focused primarily on cellular aspects of immunology and immuno-oncology can be used to summarize and visualize published research, and to analyze experimental data.
Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016
Ann-Marie Roche
The slides from the keynote given by Dr. Dan Malone RPh, PhD at the First International Drug-Drug Interaction Knowledge Representation Workshop on October 6th 2014 (http://icbo14.com/sessions/drug-drug-interaction-knowledge-representation-workshop/). Posted with his permission.
Keynote malone-clinical-relevance-of-ddi-evidence
Keynote malone-clinical-relevance-of-ddi-evidence
Richard Boyce, PhD
Learn how to use Pathway Studio to explore biomarkers and brain regions. With the addition of highly sophisticated visualization tools, users can interactively explore the vast number of connections created to help unravel disease biology. In addition, an innovative new taxonomy based on brain region identifications will be presented. Together, these innovations can be applied to rapidly increase the knowledge of diseases based on published findings.
Biomarkers brain regions
Biomarkers brain regions
Ann-Marie Roche
Overcoming obstacles to repurposing for neurodegenerative disease
Overcoming obstacles to repurposing for neurodegenerative disease
Overcoming obstacles to repurposing for neurodegenerative disease
Lona Vincent
Disease Network is the science that has emerged to diagnose a disease from a network aspect specifically. Networks are the group that interconnect to each others similarly disease networks are the one that reveal concelled connection among apparently independent biomedical entities like physiologic process, signaling receptors, in addition to genetic code, also they prove to exists intitutive in addition to powerful way to learn/discover or diagnose a disease.Due to these networks, we can now consume the elderly drugs and its method to learn/discover the new drug accordingly.Example- Colchicine is used in gout but after repurposing it is also used in mediterranean fever. This is because there are many factors that affect the body during mediterranean fever and gout, we know that gout is a form of arthritis that causes pain in joints also mediterranean fever is the one which is accompanied by pain in joints, therefore colchicine is used as a repurposed drug again.In repurposing of medicines or drugs we first analyse the change in symptoms and identify the target organ and accorgingly we produce a drug that is compatible with pharmacokinetics of the body. As the availablity of transcriptomic,proteomic and metabolomic data sources are increasing day by day it helps in classification of disease .Also there are some networks reffered to as complex networks which can be called as collection of linked junctions/ nodes
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
IJTRET-International Journal of Trendy Research in Engineering and Technology
Journal Club Presentation
Drug Safety: Fluoroquinolone
Drug Safety: Fluoroquinolone
Bhargav Darji
Drug Analytics in Embase
Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0
Ann-Marie Roche
Dr. Su Golder, NIHR Research Fellow at the University of York, presents findings from her recent publication: “Systematic review on the prevalence, frequency and comparative value of adverse events data in social media”.
Searching socialmediaforadverseevents
Searching socialmediaforadverseevents
Ann-Marie Roche
Early Clinical Development
Early Clinical Development
Rick Sax
Presented at the UC Braid Retreat: Imagine a statewide research engine of pooled resources, data, and expertise that accelerates the “translation” of academic research to direct patient benefit. That's the goal of the University of California Biomedical Research Acceleration, Integration, and Development (UC BRAID) program.
NIH Drug Discovery and Development - NCTT and CTSAs
NIH Drug Discovery and Development - NCTT and CTSAs
CTSI at UCSF
FDA approved drugs for coronavirus - docking study
Fda approved docking study
Fda approved docking study
DrShanthiSabari
Talk for conference 14th March 2012 on drug repurposing
Indications discovery and drug repurposing
Indications discovery and drug repurposing
Sean Ekins
Workshop on Using the Guide to Immunoipharmacology. PDF of slides presented at BPS Pharmacology 2019 by Dr. Simon Harding.
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Guide to PHARMACOLOGY
Poster on the IUPHAR/BPD Guide to PHARMACOLOGY presented at the ELIXIR All Hands 2020 Meeting
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Guide to PHARMACOLOGY
Web 2.0
Web presentation Ella
Web presentation Ella
0ehoogev
Natalia Gucwa
Natalia Gucwa
magdajanusz
2014 competition entry_presentation_-_template_v1.0
2014 competition entry_presentation_-_template_v1.0
thesugarbabes
Who hiv 2012.27_eng
Who hiv 2012.27_eng
clac.cab
msmgf msm gf new funding model
Gf community update_nov2013
Gf community update_nov2013
clac.cab
Acumulados 2014 precipitaciones centro humboldt
Acumulados 2014 precipitaciones centro humboldt
Centro Alexander von Humboldt
Who hiv 2012.29_eng
Who hiv 2012.29_eng
clac.cab
Regional report Latin America
Regional report Latin America
Regional report Latin America
clac.cab
Icaso, Global Fund, early outcomes
The global fund's new funding model : Early outcomes for regional Civil Socie...
The global fund's new funding model : Early outcomes for regional Civil Socie...
clac.cab
More Related Content
What's hot
The slides from the keynote given by Dr. Dan Malone RPh, PhD at the First International Drug-Drug Interaction Knowledge Representation Workshop on October 6th 2014 (http://icbo14.com/sessions/drug-drug-interaction-knowledge-representation-workshop/). Posted with his permission.
Keynote malone-clinical-relevance-of-ddi-evidence
Keynote malone-clinical-relevance-of-ddi-evidence
Richard Boyce, PhD
Learn how to use Pathway Studio to explore biomarkers and brain regions. With the addition of highly sophisticated visualization tools, users can interactively explore the vast number of connections created to help unravel disease biology. In addition, an innovative new taxonomy based on brain region identifications will be presented. Together, these innovations can be applied to rapidly increase the knowledge of diseases based on published findings.
Biomarkers brain regions
Biomarkers brain regions
Ann-Marie Roche
Overcoming obstacles to repurposing for neurodegenerative disease
Overcoming obstacles to repurposing for neurodegenerative disease
Overcoming obstacles to repurposing for neurodegenerative disease
Lona Vincent
Disease Network is the science that has emerged to diagnose a disease from a network aspect specifically. Networks are the group that interconnect to each others similarly disease networks are the one that reveal concelled connection among apparently independent biomedical entities like physiologic process, signaling receptors, in addition to genetic code, also they prove to exists intitutive in addition to powerful way to learn/discover or diagnose a disease.Due to these networks, we can now consume the elderly drugs and its method to learn/discover the new drug accordingly.Example- Colchicine is used in gout but after repurposing it is also used in mediterranean fever. This is because there are many factors that affect the body during mediterranean fever and gout, we know that gout is a form of arthritis that causes pain in joints also mediterranean fever is the one which is accompanied by pain in joints, therefore colchicine is used as a repurposed drug again.In repurposing of medicines or drugs we first analyse the change in symptoms and identify the target organ and accorgingly we produce a drug that is compatible with pharmacokinetics of the body. As the availablity of transcriptomic,proteomic and metabolomic data sources are increasing day by day it helps in classification of disease .Also there are some networks reffered to as complex networks which can be called as collection of linked junctions/ nodes
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
IJTRET-International Journal of Trendy Research in Engineering and Technology
Journal Club Presentation
Drug Safety: Fluoroquinolone
Drug Safety: Fluoroquinolone
Bhargav Darji
Drug Analytics in Embase
Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0
Ann-Marie Roche
Dr. Su Golder, NIHR Research Fellow at the University of York, presents findings from her recent publication: “Systematic review on the prevalence, frequency and comparative value of adverse events data in social media”.
Searching socialmediaforadverseevents
Searching socialmediaforadverseevents
Ann-Marie Roche
Early Clinical Development
Early Clinical Development
Rick Sax
Presented at the UC Braid Retreat: Imagine a statewide research engine of pooled resources, data, and expertise that accelerates the “translation” of academic research to direct patient benefit. That's the goal of the University of California Biomedical Research Acceleration, Integration, and Development (UC BRAID) program.
NIH Drug Discovery and Development - NCTT and CTSAs
NIH Drug Discovery and Development - NCTT and CTSAs
CTSI at UCSF
FDA approved drugs for coronavirus - docking study
Fda approved docking study
Fda approved docking study
DrShanthiSabari
Talk for conference 14th March 2012 on drug repurposing
Indications discovery and drug repurposing
Indications discovery and drug repurposing
Sean Ekins
Workshop on Using the Guide to Immunoipharmacology. PDF of slides presented at BPS Pharmacology 2019 by Dr. Simon Harding.
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Guide to PHARMACOLOGY
Poster on the IUPHAR/BPD Guide to PHARMACOLOGY presented at the ELIXIR All Hands 2020 Meeting
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Guide to PHARMACOLOGY
What's hot
(13)
Keynote malone-clinical-relevance-of-ddi-evidence
Keynote malone-clinical-relevance-of-ddi-evidence
Biomarkers brain regions
Biomarkers brain regions
Overcoming obstacles to repurposing for neurodegenerative disease
Overcoming obstacles to repurposing for neurodegenerative disease
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
Drug Safety: Fluoroquinolone
Drug Safety: Fluoroquinolone
Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0
Searching socialmediaforadverseevents
Searching socialmediaforadverseevents
Early Clinical Development
Early Clinical Development
NIH Drug Discovery and Development - NCTT and CTSAs
NIH Drug Discovery and Development - NCTT and CTSAs
Fda approved docking study
Fda approved docking study
Indications discovery and drug repurposing
Indications discovery and drug repurposing
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Harding_ImmunopharmacologyWorkshop_Pharmacology2019
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Guide to Pharmacology Poster - ELIXIR All Hands 2020
Viewers also liked
Web 2.0
Web presentation Ella
Web presentation Ella
0ehoogev
Natalia Gucwa
Natalia Gucwa
magdajanusz
2014 competition entry_presentation_-_template_v1.0
2014 competition entry_presentation_-_template_v1.0
thesugarbabes
Who hiv 2012.27_eng
Who hiv 2012.27_eng
clac.cab
msmgf msm gf new funding model
Gf community update_nov2013
Gf community update_nov2013
clac.cab
Acumulados 2014 precipitaciones centro humboldt
Acumulados 2014 precipitaciones centro humboldt
Centro Alexander von Humboldt
Who hiv 2012.29_eng
Who hiv 2012.29_eng
clac.cab
Regional report Latin America
Regional report Latin America
Regional report Latin America
clac.cab
Icaso, Global Fund, early outcomes
The global fund's new funding model : Early outcomes for regional Civil Socie...
The global fund's new funding model : Early outcomes for regional Civil Socie...
clac.cab
Annual report 2014
HIV and Human Rights in Southern and East Africa
HIV and Human Rights in Southern and East Africa
clac.cab
B2Gold has to go! Struggle against Canadian open cast gold mining in the North of Nicaragua. Birgit Müller, FOEI.
Reportaje Rancho Grande- versión ingles
Reportaje Rancho Grande- versión ingles
Centro Alexander von Humboldt
ікони з бурштину
ікони з бурштину
Nazar19
2014 03 12 new funding model allocation external_short
2014 03 12 new funding model allocation external_short
clac.cab
PRISMA PRODUCTION merupakan event organizer yang berlokasi di Denpasar Bali, dengan ruang lingkup pekerjaan seperti : event organizer, MICE (meeting-incentive-conference-exhibition), outbound, brand activation, production (produksi, stage, rigging, sound system, talent dll) www.eventorganiserbali.com the best partner for your event
Compro prisma 2015 ver 5.1
Compro prisma 2015 ver 5.1
GOOD Bali Holiday Villas
Viewers also liked
(14)
Web presentation Ella
Web presentation Ella
Natalia Gucwa
Natalia Gucwa
2014 competition entry_presentation_-_template_v1.0
2014 competition entry_presentation_-_template_v1.0
Who hiv 2012.27_eng
Who hiv 2012.27_eng
Gf community update_nov2013
Gf community update_nov2013
Acumulados 2014 precipitaciones centro humboldt
Acumulados 2014 precipitaciones centro humboldt
Who hiv 2012.29_eng
Who hiv 2012.29_eng
Regional report Latin America
Regional report Latin America
The global fund's new funding model : Early outcomes for regional Civil Socie...
The global fund's new funding model : Early outcomes for regional Civil Socie...
HIV and Human Rights in Southern and East Africa
HIV and Human Rights in Southern and East Africa
Reportaje Rancho Grande- versión ingles
Reportaje Rancho Grande- versión ingles
ікони з бурштину
ікони з бурштину
2014 03 12 new funding model allocation external_short
2014 03 12 new funding model allocation external_short
Compro prisma 2015 ver 5.1
Compro prisma 2015 ver 5.1
Similar to Who hiv 2012.28_eng
Embase webinar pico search strategies as of 042115v3
Embase webinar pico search strategies as of 042115v3
Ann-Marie Roche
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Yusuf Misau
JHVRV-02-00047 (final)
JHVRV-02-00047 (final)
Inalegwu Oono
Repurposed existing drugs and updated global health policy and clinical guidelines will be essential for limiting the social and economic devastation caused by this virus. So, we are leading a three-phase multinational Network Medicine clinical study (MNM COVID-19 study). The study will apply Network Medicine methodologies to repurpose existing drugs for SARS-CoV-2 infected patients and update global health policy and clinical guidelines.
MNM COVID-19 Study
MNM COVID-19 Study
Michael Fritz
Keynote presentation: Clinical Research Informatics & Implementation Science Year-in-Review, presented at the AMIA Informatics Summit, 2023. This covers major publications in CRI during latter part of 2021 through March 15, 2023.
Clinical Research Informatics Year-in-Review - 2023
Clinical Research Informatics Year-in-Review - 2023
Peter Embi
Background:The use of CD4+ T Lymphocyte count as a vital component to ascertain the stage of HIV/AIDS disease as well as monitor the progress of the disease continues to take centre stage in the management of HIV/AIDS in Africa and beyond. Most health centres in Sub-saharan Africa rely on cut off reference values from different races and distant parts of the world. Aim:This study was designed to establish the range of CD4+ T Lymphocyte counts among the HIV-negative individuals and also HIV-positive patients at initial booking in the anti-retroviral clinic of our hospital where clinical diagnosis was established. Methods:Patients were recruited into the study as they report to the hospital on daily basis; structured questionnaires were administered where socio-demograhic and relevant clinical information were obtained. Blood samples (3-5mls) were collected using aseptic techniqueand processed where HIV screening was conducted, and CD4+ T Lymphocyte cell count was carried out using Cyflow (Partec, Germany). Results were fed into Microsoft excel 2007 version and analysed using SPSS 14. Results:A total of 386 HIV-positive and 145 HIV-negative individuals were recruited into the study. The average CD4+ T Lymphocytes count among the HIV negative individuals was 850 cells /μL and ranged from 200 to 1950 cells/μL with CD4+ T Lymphocyte counts of less than 300 cells/μL being 5 (3.4%). The CD4+ T Lymphocyte counts of less than 500 cells/μL among the HIV-negative individuals was 19(13.1%). However, the CD4+ T Lymphocyte counts among HIV-infected individuals ranged from 50 to 1450 cells/μL, 0.8% (n=3) while 45.9% (n=177) presented with CD4+ T Lymhocyte counts of 50 or less and less than 250 cells/μL respectively. The fact that 75.9% (n=293) of the patients had a CD4+ T Lymphocyte counts of less than 500 cells/μL shows the general late presentation of patients with HIV infection at our health settings, and as much as 50% of these were aware of their HIV status the very first time.
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
IjcmsdrJournal
Steroid Research
Steroid Research
Mark Kennedy
highest level of evidence in clinical research
systematic review and metaanalysis
systematic review and metaanalysis
DrSridevi NH
How To Get Your Research Published in the BMJ
How To Get Your Research Published in the BMJ
bmjslides
Evaluating and Investigating Drug Safety Signals with Public Databases
Evaluating and Investigating Drug Safety Signals with Public Databases
Perficient
DUE 11/6/2017 10 P.M EST THIS IS A 4 PART HIV SPSS PROJECT. ATTACHED IS THE PREVIOUS PARTS. PLEASE READ IT ALL. WHEN YOU GENERATE IT, I’M SURE IT WILL BE A LITTLE DIFFERENT BUT THAT’S O.K.. THE ANALYSIS IS ALSO ATTACHED. For your Final Project submission, you have the opportunity to share the significance of your results in the practice of public health. With your disease and data in mind, integrate instructor and peer feedback you have received throughout the course, in completing your statistical analyses. The Assignment: (7 PAGES) · Section I: Introduction (3 pages) · Brief description of your identified disease · Summary of other studies that directly relate to your identified disease outcome (Note: This is essentially the Literature Review you submitted in Week 6. There is no need to include the Annotated Bibliography as well since it was developed into your Literature Review.) · Statement of the Problem/Research question · Written statements for both your null and alternative/research hypothesis · Brief description of the significance of why this disease is important for examination · · Section II: Methodology (1 page) · Brief description of the study sample · Description of the data gathering methods for your variables of interest · Explanation of the types of statistical analyses you conducted and why · · Section III: Results (2 PAGES) · Description of the steps you took to conduct your statistical analyses · Summary of your statistical findings · Narrative description · Tables and graphs (Be careful—too many tables and graphs decreases clarity) · · Section IV: Conclusions and Discussion (1 PAGE · Explanation of your major results (Be sure to answer your research question.) · If appropriate, report on statistical significance (or not) of your results; including any relationship between your variables of interest. · Social change implications of your results for the population that was sampled from. · Suggestions for future research. · Appendices · SPSS Codebook · Syntax Code (step-by-step instructions of how to run the different analyses) · References Include 4–6 peer-reviewed resources. Be sure to follow APA format. FINAL PROJECT: TOPIC, STATEMENT OF PROBLEM, AND ANNOTATED BIOGRAPHY (DIRECTIONS) As a public health professional, you may research many areas of interest. For example, in studying how economics affects global health, what variables might you consider? In examining these variables, you may consider the significance of why this issue is essential for analysis. For this Assignment, you will explore the Final Project dataset provided in the Course Information tab and select one of the following diseases (dependent variables): H.I.V. You will examine the other (independent) variables available in the dataset. They include demographic variables (i.e., gender, age, race/ethnicity, income, education, insurance, urban residence, and region), clinical risk factors (i.e., BMI and cholesterol), and behavioral risk factors (i.e. ...
DUE 1162017 10 P.M ESTTHIS IS A 4 PART HIV SPSS PROJECT. ATTAC.docx
DUE 1162017 10 P.M ESTTHIS IS A 4 PART HIV SPSS PROJECT. ATTAC.docx
sagarlesley
Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs Jason Grebely1 , Sarah Larney2 , Amy Peacock2 , Samantha Colledge2 , Janni Leung2,3 , Matthew Hickman4 , Peter Vickerman4 , Sarah Blach5 , Evan B. Cunningham1 , Kostyantyn Dumchev6 , Michael Lynskey7 , Jack Stone4 , Adam Trickey4 , Homie Razavi5 , Richard P. Mattick2, Michael Farrell2 , Gregory J. Dore1 & Louisa Degenhardt2 The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia,1 National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia,2 School of Public Health, Faculty of Medicine, University of Queensland, QLD, Australia,3 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK,4 CDA Foundation, Lafayette, CO, USA,5 Ukrainian Institute on Public Health Policy, Kiev, Ukraine6 and National Addiction Centre, King’s College London, London, UK7 ABSTRACT Background and Aims People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels. Methods Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These datawere combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. Results There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4–9.2] people with recent injecting drug use aged 15–64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6–47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0–2.1), eastern Europe (1.5 million, UI = 0.7–2.4) and North America (1.0 million, UI = 0.4–1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6–13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7–56.7), Latin America (22.0%, UI = 15.3–30.4) and eastern Europe (17.9%, UI = 8.2–30.9). Conclusions Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions. Keywords Estimates, HCV, IDU, injecting drug use, PWID, viraemic. Correspondence to: Jason Grebely, The Kirby Institute, Level 6, Wallace Wurth Building, UNSW Sydney, Sydney, NSW 2052, Australia. E-mail: [email protected] Submitted 8 January 2018; initial review completed 29 March 2018; final version accepted 12 J ...
Global, regional, and country-level estimates of hepatitisC .docx
Global, regional, and country-level estimates of hepatitisC .docx
shericehewat
The Association between Motivational Subtypes and Medical Cannabis Consumption: A 30-Day Diary Study
Cannabis Science & Policy Summit - Day 2 - Novak
Cannabis Science & Policy Summit - Day 2 - Novak
CannabisSummit
Profile of drug users
Profile of drug users
Mark Kennedy
Description db
Embase.pdf
Embase.pdf
AntonellaDiNisio1
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related TUBERCULOSIS) DISCLAIMER- Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related ...
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related ...
Global Medical Cures™
• A brief introduction about relevance of literature screening for P V. • Challenges of literature screening in general. • Benefits and risks of completely outsourcing literature screening for PV. • Business case elements that need to take into consideration when deciding on outsourcing or in-sourcing PV literature screening.
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Julio dos Anjos
Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)
Ann-Marie Roche
The Transtheoretical Model also called the Stages of Change model,7 describes how such behavior change often occurs. The model emphasizes the need to understand the experience of the person we are trying to reach in order to help them. To promote change, interventions must be provided that are appropriate for the stage in the process that people are in." "Meet people where they are: The guiding principle of “meeting people where they are” means more than showing compassion or tolerance to people in crisis. This principle also asks us to acknowledge that all people we meet are at different stages of behavior change."
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
Cassondra Turner McArthur
COVID-19- Vaccines: Trends & Future: Systematic Review & Meta Analysis
COVID-19- Vaccines: Trends & Future: Systematic Review & Meta Analysis
COVID-19- Vaccines: Trends & Future: Systematic Review & Meta Analysis
DrHeena tiwari
Similar to Who hiv 2012.28_eng
(20)
Embase webinar pico search strategies as of 042115v3
Embase webinar pico search strategies as of 042115v3
Systematic Review Of Observational Studies By Yusuf Abdu Misau
Systematic Review Of Observational Studies By Yusuf Abdu Misau
JHVRV-02-00047 (final)
JHVRV-02-00047 (final)
MNM COVID-19 Study
MNM COVID-19 Study
Clinical Research Informatics Year-in-Review - 2023
Clinical Research Informatics Year-in-Review - 2023
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Steroid Research
Steroid Research
systematic review and metaanalysis
systematic review and metaanalysis
How To Get Your Research Published in the BMJ
How To Get Your Research Published in the BMJ
Evaluating and Investigating Drug Safety Signals with Public Databases
Evaluating and Investigating Drug Safety Signals with Public Databases
DUE 1162017 10 P.M ESTTHIS IS A 4 PART HIV SPSS PROJECT. ATTAC.docx
DUE 1162017 10 P.M ESTTHIS IS A 4 PART HIV SPSS PROJECT. ATTAC.docx
Global, regional, and country-level estimates of hepatitisC .docx
Global, regional, and country-level estimates of hepatitisC .docx
Cannabis Science & Policy Summit - Day 2 - Novak
Cannabis Science & Policy Summit - Day 2 - Novak
Profile of drug users
Profile of drug users
Embase.pdf
Embase.pdf
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related ...
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related ...
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
COVID-19- Vaccines: Trends & Future: Systematic Review & Meta Analysis
COVID-19- Vaccines: Trends & Future: Systematic Review & Meta Analysis
More from clac.cab
Community update 2014
Community update 2014
Community update 2014
clac.cab
32nd board meeting communities delegation country dialogue position paper
32nd board meeting communities delegation country dialogue position paper
32nd board meeting communities delegation country dialogue position paper
clac.cab
EFFECTIVE ENGAGEMENT OF COMMUNITIES IN THE COUNTRY DIALOGUE PROCESSES
Engagement of key populations in the funding model report
Engagement of key populations in the funding model report
clac.cab
Explanation of Band 4 of the Global Fund to Fight AIDS, Tuberculosis and Malaria and its Implications for Civil Society and Key Populations
Punishing success ?
Punishing success ?
clac.cab
Why advocacymatters
Why advocacymatters
Why advocacymatters
clac.cab
The needs and rights of male sex workers briefing paper
The needs and rights of male sex workers
The needs and rights of male sex workers
clac.cab
The needs and rights of male sex workers summary
The needs and rights of male sex workers (summary)
The needs and rights of male sex workers (summary)
clac.cab
Dialogue Pays
Dialogue Pays
clac.cab
Prochaine etapes
Prochaine etapes
clac.cab
Nfm complete presentation fr
Nfm complete presentation fr
clac.cab
Nfm complet francais
Nfm complet francais
clac.cab
Nadia tunis - Dialogue pays, société civile,note conceptuelle et ex d'autres ...
Nadia tunis - Dialogue pays, société civile,note conceptuelle et ex d'autres ...
clac.cab
La dynamique de l’épidémie de vih en tunisie
La dynamique de l’épidémie de vih en tunisie
clac.cab
Agenda atelier
Agenda atelier
clac.cab
20140508 cartographie des_modalités_de_mise_en_œuv re (1)
20140508 cartographie des_modalités_de_mise_en_œuv re (1)
clac.cab
Droits humains et vih
Droits humains et vih
clac.cab
GNP+ SALUD, DIGNIDAD Y PREVENCIÓN POSITIVAS Guidance
SALUD, DIGNIDAD Y PREVENCIÓN POSITIVAS